It’s not unusual for young biotechs to show earl

It’s not unusual for young biotechs to show early success in phase 1 trials like we have. But the fascinating part of this is the success in areas where others have failed. Taking on cancer, Nash, long haulers, etc.is huge in the medical world. These are extremely difficult diseases to tackle. Personally, I think Dr Kelley has quite an audience amongst big pharma and I look for news on a joint venture sometime after the first of the year. Just an educated guess based on my 40 plus years in the financial world.